Why Did Phathom Pharmaceuticals Soar 24.47%?

On April 9, 2025, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) surged 24.47% in pre-market trading, marking a significant rise in its stock price.

Analysts have set a price target of $22.17 for Phathom Pharmaceuticals, reflecting optimism about the company's future prospects. However, Jefferies has lowered its price target from $17 to $13, citing that the current share price already reflects positive developments. Despite this, Jefferies maintains a Buy recommendation, while H.C. Wainwright has reaffirmed its Buy rating.

Phathom Pharmaceuticals' CFO, Molly Henderson, sold 3,678 shares of common stock on April 7, 2025, at an average price of $4.5513 per share. This transaction has raised questions about insider sentiment, as the average selling price is lower than the current share price, suggesting that insiders might have benefited more by holding onto their shares.